ERBB3 and non-small cell lung carcinoma: Loss of Her3 associated with EMT may confer resistance to Her3 targeting agents, such as the anti-Her3 monoclonal antibody MM-121, which is currently being assessed in patients with advanced NSCLC as a phase I/II trial (ClinicalTrials.gov identifier NCT00994123).